58 related articles for article (PubMed ID: 17625431)
1. Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review.
Wigfield P; Sbarigia U; Hashim M; Vincken T; Heeg B
Pharmacoecon Open; 2020 Sep; 4(3):403-418. PubMed ID: 31428938
[TBL] [Abstract][Full Text] [Related]
2. Estimating the potential annual welfare impact of innovative drugs in use in Switzerland.
Pavic M; Pfeil AM; Szucs TD
Front Public Health; 2014; 2():48. PubMed ID: 24904912
[TBL] [Abstract][Full Text] [Related]
3. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
Tantai N; Chaikledkaew U; Tanwandee T; Werayingyong P; Teerawattananon Y
BMC Health Serv Res; 2014 Apr; 14():170. PubMed ID: 24731689
[TBL] [Abstract][Full Text] [Related]
4. The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis.
Mealing S; Ghement I; Hawkins N; Scott DA; Lescrauwaet B; Watt M; Thursz M; Lampertico P; Mantovani L; Morais E; Bregman B; Cucherat M
Syst Rev; 2014 Mar; 3():21. PubMed ID: 24602249
[TBL] [Abstract][Full Text] [Related]
5. Disease burden of chronic hepatitis B among immigrants in Canada.
Wong WW; Woo G; Heathcote EJ; Krahn M
Can J Gastroenterol; 2013 Mar; 27(3):137-47. PubMed ID: 23516678
[TBL] [Abstract][Full Text] [Related]
6. The use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients.
Ali S; Mealing S; Hawkins N; Lescrauwaet B; Bjork S; Mantovani L; Lampertico P
BMJ Open; 2013 Jan; 3(1):. PubMed ID: 23355658
[TBL] [Abstract][Full Text] [Related]
7. Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B.
Keating GM
Drugs; 2009; 69(18):2633-60. PubMed ID: 19943712
[TBL] [Abstract][Full Text] [Related]
8. The economics of treating chronic hepatitis B in Asia.
Dan YY; Aung MO; Lim SG
Hepatol Int; 2008 Sep; 2(3):284-95. PubMed ID: 19669256
[TBL] [Abstract][Full Text] [Related]
9. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B.
Spackman DE; Veenstra DL
Pharmacoeconomics; 2008; 26(11):937-49. PubMed ID: 18850763
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.
Vanagas G; Padaiga Z; Mickevičienė A
Medicina (Kaunas); 2010; 46(12):835-42. PubMed ID: 21532288
[TBL] [Abstract][Full Text] [Related]
11. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
12. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B.
Takeda A; Jones J; Shepherd J; Davidson P; Price A
J Viral Hepat; 2007 Feb; 14(2):75-88. PubMed ID: 17244247
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.
Veenstra DL; Sullivan SD; Dusheiko GM; Jacobs M; Aledort JE; Lewis G; Patel KK
Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):631-8. PubMed ID: 17625431
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.
Sullivan SD; Veenstra DL; Chen PJ; Chang TT; Chuang WL; Tsai C; Patel K
J Gastroenterol Hepatol; 2007 Sep; 22(9):1494-9. PubMed ID: 17716353
[TBL] [Abstract][Full Text] [Related]
15. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan.
Veenstra DL; Sullivan SD; Lai MY; Lee CM; Tsai CM; Patel KK
Value Health; 2008; 11(2):131-8. PubMed ID: 18380625
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
